These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
408 related articles for article (PubMed ID: 18173626)
21. Efficacy and tolerability of levetiracetam in children younger than 4 years: a retrospective review. Perry MS; Benatar M Epilepsia; 2007 Jun; 48(6):1123-7. PubMed ID: 17430408 [TBL] [Abstract][Full Text] [Related]
22. Efficacy of levetiracetam in the treatment of drug-resistant Rett syndrome. Specchio N; Balestri M; Striano P; Cilio MR; Nardello R; Patanè S; Margiotta ML; D'Orsi G; Striano S; Russo S; Specchio LM; Cusmai R; Fusco L; Vigevano F Epilepsy Res; 2010 Feb; 88(2-3):112-7. PubMed ID: 19914805 [TBL] [Abstract][Full Text] [Related]
23. Levetiracetam and Valproate Retention Rate in Juvenile Myoclonic Epilepsy. Sala-Padró J; Toledo M; Santamarina E; González-Cuevas M; Raspall-Chaure M; Sueiras-Gil M; Quintana M; Salas-Puig X Clin Neuropharmacol; 2016; 39(6):299-301. PubMed ID: 27438183 [TBL] [Abstract][Full Text] [Related]
24. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial. Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM; Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886 [TBL] [Abstract][Full Text] [Related]
25. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy. Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453 [TBL] [Abstract][Full Text] [Related]
26. Levetiracetam in adult patients with and without learning disability: focus on behavioral adverse effects. Brodtkorb E; Klees TM; Nakken KO; Lossius R; Johannessen SI Epilepsy Behav; 2004 Apr; 5(2):231-5. PubMed ID: 15123025 [TBL] [Abstract][Full Text] [Related]
27. Levetiracetam in newly diagnosed late-onset post-stroke seizures: a prospective observational study. Belcastro V; Costa C; Galletti F; Autuori A; Pierguidi L; Pisani F; Calabresi P; Parnetti L Epilepsy Res; 2008 Dec; 82(2-3):223-6. PubMed ID: 18829259 [TBL] [Abstract][Full Text] [Related]
28. Intravenous levetiracetam in children with seizures: a prospective safety study. Ng YT; Hastriter EV; Cardenas JF; Khoury EM; Chapman KE J Child Neurol; 2010 May; 25(5):551-5. PubMed ID: 20413804 [TBL] [Abstract][Full Text] [Related]
29. Preliminary efficacy of levetiracetam in monotherapy. Ben-Menachem E Epileptic Disord; 2003 May; 5 Suppl 1():S51-5. PubMed ID: 12915342 [TBL] [Abstract][Full Text] [Related]
30. Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate. Chowdhury A; Brodie MJ Epilepsy Res; 2016 Jan; 119():62-6. PubMed ID: 26675554 [TBL] [Abstract][Full Text] [Related]
31. Levetiracetam versus carbamazepine monotherapy for partial epilepsy in children less than 16 years of age. Perry S; Holt P; Benatar M J Child Neurol; 2008 May; 23(5):515-9. PubMed ID: 18182645 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy. Li S; Cao J; Xiao N; Cai F J Child Neurol; 2010 May; 25(5):609-13. PubMed ID: 19779208 [TBL] [Abstract][Full Text] [Related]
33. Levetiracetam: a long-term follow-up study of efficacy and safety. Bauer J; Ben-Menachem E; Krämer G; Fryze W; Da Silva S; Kasteleijn-Nolst Trenité DG Acta Neurol Scand; 2006 Sep; 114(3):169-76. PubMed ID: 16911344 [TBL] [Abstract][Full Text] [Related]
34. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial. Coppola G; Franzoni E; Verrotti A; Garone C; Sarajlija J; Operto FF; Pascotto A Brain Dev; 2007 Jun; 29(5):281-4. PubMed ID: 17055681 [TBL] [Abstract][Full Text] [Related]
35. Levetiracetam in patients with epilepsy and chronic liver disease: observations in a case series. Bilo L; Meo R; de Leva MF; De Simone R; Di Nocera P; Pisani F; Striano S Clin Neuropharmacol; 2008; 31(4):221-5. PubMed ID: 18670245 [TBL] [Abstract][Full Text] [Related]
36. Adjunctive levetiracetam in patients aged 1 month to <4 years with partial-onset seizures: subpopulation analysis of a prospective, open-label extension study of up to 48 weeks. Piña-Garza JE; Schiemann-Delgado J; Yang H; Duncan B; Hadac J; Hunter SJ Clin Ther; 2010 Oct; 32(11):1935-50. PubMed ID: 21095488 [TBL] [Abstract][Full Text] [Related]
37. Predictors for long-term seizure outcome in juvenile myoclonic epilepsy: 25-63 years of follow-up. Geithner J; Schneider F; Wang Z; Berneiser J; Herzer R; Kessler C; Runge U Epilepsia; 2012 Aug; 53(8):1379-86. PubMed ID: 22686598 [TBL] [Abstract][Full Text] [Related]
38. Clinical and neuropsychological considerations in a case of unrecognized myoclonic epileptic jerks dramatically controlled by levetiracetam. Gentile V; Brunetto D; Leo I; Bonetti S; Verrotti A; Franzoni E Neuropediatrics; 2010 Dec; 41(6):270-2. PubMed ID: 21445819 [TBL] [Abstract][Full Text] [Related]
39. Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy. Coppola G; Mangano S; Tortorella G; Pelliccia A; Fels A; Romano A; Nardello R; Habetswallner F; Licciardi F; Operto FF; Pascotto A Epilepsy Res; 2004 Mar; 59(1):35-42. PubMed ID: 15135165 [TBL] [Abstract][Full Text] [Related]
40. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Glauser TA; Ayala R; Elterman RD; Mitchell WG; Van Orman CB; Gauer LJ; Lu Z; Neurology; 2006 Jun; 66(11):1654-60. PubMed ID: 16641323 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]